TABLE 1.
Demographics of the study populationa
| Parameter | Value for group |
||
|---|---|---|---|
| Total | HIV POCT positive | HIV POCT negative | |
| Neonates and children | |||
| Total no. enrolledb | 322 | 102 | 220 |
| Median age, days (IQR) | 1 (1–13) | 79 (11–222) | 1 (1–1) |
| Age (no.) | |||
| <7 days | 225 | 13 | 212 |
| 7–<28 days | 28 | 24 | 4 |
| 28 days–<12 mo | 52 | 49 | 3 |
| 12–<18 mo | 17 | 16 | 1 |
| Gender (no.) | |||
| Female | 168 | 58 | 110 |
| Male | 154 | 44 | 110 |
| Mothers | |||
| Total no. enrolledb | 311 | 102 | 209 |
| Median age, yr (IQR) | 30 (25–35) | 27 (25–33) | 31 (26–36) |
| PMTCT (no.) | |||
| Yes | 261 | 65 | 196 |
| No | 46 | 33 | 13 |
| Unknown | 4 | 4 | 0 |
| Median PMTCT duration, wk (IQR) | 18 (0–30) | 13 (0–27) | 21 (14–34) |
| cART (no.) | |||
| <12 wk | 82 | 46 | 36 |
| Preconception | 61 | 14 | 47 |
a
Study participants were grouped according to their point-of-care HIV result. Four participants with inconclusive SOC results were included based on their POC result. IQR, interquartile range; PMTCT, prevention of mother-to-child transmission; cART, combination antiretroviral therapy.
b
Eleven sets of twins were enrolled in the study.